Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.6094
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 145659179400.0
- FreeCF/Share 1.9771
- PFCF 12.9821
- PE 18.4838
- Debt/Assets 0.2946
- DivYield 0.0827
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
Will The Tariff “Taco Trade” End The Rally? 5 High-Yield Value Stocks Are Strong Buys Now
Published: July 07, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Value stocks are generally companies that trade at a price lower than their fundamental value or what their performance suggests they should be worth.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (July 2025)
Published: July 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
Shares of Pfizer ( NYSE: PFE ) surged 8.24% over the past month, reducing the stock's year-to-date loss to 5.02%.
Read More
2 Stocks to Buy With Less Than $50
Published: July 04, 2025 by: The Motley Fool
Sentiment: Positive
One formula to generate strong returns on equity markets involves investing small amounts of money in top stocks regularly over long periods. Buying fractional shares is one way to apply this strategy, but it's also possible to find attractive corporations at already-affordable prices.
Read More
Pfizer: Options Activity Speaks Bullish
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive
The call activity above the current Pfizer Inc. share price, increasing call premiums, and the lack of defensive put buying point to options traders expecting Pfizer to move higher from current price. Cost-saving initiatives, strong free cash flow, and a large R&D budget, support future growth and innovation, with recent pipeline successes as catalysts. Despite macro risks and ROIC below historical averages, PFE stock's 52% upside to fair value and compelling yield make it a rare value opportunity.
Read More
Pfizer Trades Above 50-Day Average for a Month: Time to Buy?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE trades above its 50-day average for over a month, signaling bullish momentum despite COVID revenue declines and patent risks.
Read More
Pfizer (PFE) Outperforms Broader Market: What You Need to Know
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
In the latest trading session, Pfizer (PFE) closed at $25.32, marking a +1.12% move from the previous day.
Read More
Cannabis Lighting Market Report 2025-2030 | Share Analysis, Industry Trends & Statistics, Growth Forecasts - Pfizer Ventures into Cannabis with $6.7 Billion Deal, Boosting Industry Growth
Published: July 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North America leading. New launches by companies like OSRAM enhance growth. The Cannabis Lighting Market is set to grow at a CAGR of 7.6% during the forecast period, driven by rising medical cannabis use and cultivation. Key players like Pfizer are entering the market. LED lights are a major trend due to energy efficiency, with North …
Read More
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.
Read More
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's Hympavzi meets key phase III goals, demonstrating a significant reduction in bleeding in hemophilia patients with inhibitors.
Read More
All You Need to Know About Pfizer (PFE) Rating Upgrade to Buy
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Don't Sleep On Pfizer: The Turnaround Is Just Getting Started
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive
Despite a revenue miss, Pfizer's Q1 earnings crushed estimates due to aggressive, structural cost-cutting, signaling a powerful shift towards operational and margin excellence. Management is expanding its cost-savings program to a massive $7.7 billion by 2027, aiming to create a powerful EPS growth story despite flat revenues. Pfizer's non-COVID portfolio is firing on all cylinders, with key drugs like Nurtec and Padcev showing robust double-digit growth, proving underlying business health.
Read More
17 Ideal 'Safer' Dividend Dogs To Buy Out Of 72 June Graham Value All-Stars
Published: June 25, 2025 by: Seeking Alpha
Sentiment: Positive
I use YCharts' Value Score and Ben Graham Formula Value All Stars, or GASV, to identify large-cap stocks offering strong value and dividend safety. Seventeen out of twenty-four "safer" lowest-priced Dividend Dogs of the GASV are currently fair-priced and ready to buy for income investors. Top ten GASV stocks offer projected average net gains of 32.99% by June 2026, with yields ranging from 8.94% to 13.81%.
Read More
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
Published: June 25, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. In.
Read More
Pfizer to Face Several Headwinds: Can It Successfully Navigate Them?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Negative
PFE faces a decline in COVID revenues, LOE pressure and IRA impacts but rising EPS estimates offer a glimmer of resilience.
Read More
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.
Read More
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Read More
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.
Read More
RFK Jr weighs review of vaccines citing aluminum use, Bloomberg News reports
Published: June 18, 2025 by: Reuters
Sentiment: Neutral
U.S. Health Secretary Robert F. Kennedy Jr. is considering asking a key government vaccine advisory panel to examine vaccines that contain aluminum ingredients, Bloomberg News reported on Wednesday, citing a source familiar with the matter.
Read More
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
Published: June 18, 2025 by: CNBC
Sentiment: Neutral
A revamped government panel of vaccine advisors appointed by Health and Human Services Secretary Robert F. Kennedy Jr. will soon vote on a shot preservative that contains mercury, which is safely used in some flu jabs but has been incorrectly linked to autism in the past.
Read More
3 High-Yield Dividend Stocks Increasing Payouts For Decades
Published: June 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
These dividend stocks have high yields and solid upside potential. They also have quality underlying businesses.
Read More
Should Value Investors Buy Pfizer (PFE) Stock?
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
5 Low Price-to-Book Value Stocks That You Can Buy in June
Published: June 17, 2025 by: Zacks Investment Research
Sentiment: Positive
The P/B ratio helps to identify low-priced stocks with high growth prospects. USNA, CVS, PFE, STNE and PSFE are some such stocks.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
4 Value Stocks to Shield Your Portfolio Amid Geopolitical Turmoil
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
As geopolitical risks jolt markets, STNE, CNC, CVS and PFE shine with low cash flow valuations and solid earnings outlooks.
Read More
5 Large Drug Stocks That Are Poised to Ride on Sector Recovery
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the Large-Cap Pharmaceuticals industry, AbbVie, Novartis, Pfizer, Sanofi and Bayer are worth retaining amid macro pressure and rising innovation.
Read More
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA, June 12, 2025 (GLOBE NEWSWIRE) -- Berger Montague advises shareholders of Pfizer Inc. (“Pfizer” or the “Company”) (NYSE: PFE) about an investigation into Pfizer's Board of Directors for potential breaches of fiduciary duties to Pfizer and its shareholders in connection with the Company's marketing and sale of Depo-Provera.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000